Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 31, Iss. 1, 2018-01 ,pp. : 110-114

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phosphoproteomic analysis of basal and therapy‐induced adaptive signaling networks in BRAF and NRAS mutant melanoma

By  

PROTEOMICS, Vol. 15, Iss. 2-3, 2015-01 ,pp. : 327-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia

By Emadi Ashkan   Bade Najeebah A.   Stevenson Brandi   Singh Zeba  

Pharmaceuticals, Vol. 9, Iss. 1, 2016-03 ,pp. : 12-12

MDPI

Access to resources Recommend Favorite

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer

By Kim Jae-Young   Stewart Paul A.   Borne Adam L.   Fang Bin   Welsh Eric A.   Chen Yian Ann   Eschrich Steven A.   Koomen John M.   Haura Eric B.  

Proteomes, Vol. 4, Iss. 2, 2016-04 ,pp. : 16-16

MDPI

Access to resources Recommend Favorite

Induction of Apoptosis by 11-Dehydrosinulariolide via Mitochondrial Dysregulation and ER Stress Pathways in Human Melanoma Cells

By Su Tzu-Rong   Tsai Feng-Jen   Lin Jen-Jie   Huang Han Hsiang   Chiu Chien-Chih   Su Jui-Hsin   Yang Ya-Ting   Chen Jeff Yi-Fu   Wong Bing-Sang   Wu Yu-Jen  

Marine Drugs, Vol. 10, Iss. 8, 2012-08 ,pp. : 1883-1898

MDPI

Access to resources Recommend Favorite